News
After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...
Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.
Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...
Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...
Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
10h
Barchart on MSNKenvue's Q2 2025 Earnings: What to ExpectSkillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market ...
If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...
Kenvue Inc. has announced a leadership change and the initiation of a strategic review aimed at optimizing its brand portfolio and operating model. Kirk Perry, a Kenvue board member and former ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...
The stock's fall snapped a four-day winning streak.
We recently published 10 Stocks Jim Cramer Discussed As He Commented On Latest Tariffs. Kenvue Inc. (NYSE:KVUE) is one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results